Details for Patent: 6,017,900
✉ Email this page to a colleague
Title: | Topical composition containing hyaluronic acid and nsaids |
Abstract: | A pharmaceutical composition comprising a plurality of effective non-toxic dosage amounts of a composition for topical administration to the site of pathology or trauma of skin or exposed tissue of a human patient in need of treatment suffering from a disease or condition, each such dosage amount comprising a therapeutically effective non-toxic dosage amount of a drug for the treatment of the disease or condition of the skin or exposed tissue at the site of the pathology or trauma and an effective non-toxic dosage amount of hyaluronic acid or salts thereof or homologues, analogues, derivatives, complexes, esters, fragments, or sub-units of hyaluronic acid to transport the drug to the site of the pathology or trauma of the disease or condition. |
Inventor(s): | Falk; Rudolf Edgar (Toronto, CA), Asculai; Samuel Simon (Toronto, CA) |
Assignee: | Hyal Pharmaceutical Corporation (Missisauga, CA) |
Filing Date: | Jun 06, 1995 |
Application Number: | 08/466,775 |
Claims: | 1. A pharmaceutical composition comprising a plurality of effective non-toxic dosage amounts of a composition for topical administration to a site of pathology or trauma of skin or exposed tissue of a human patient in need of treatment suffering from a disease or condition, each such dosage amount comprising a therapeutically effective non-toxic dosage amount of a drug for the treatment of the disease or condition of the skin or exposed tissue at the site of the pathology or trauma and an effective non-toxic dosage amount of at least about 5 mg/cm.sup.2 of a form of hyaluronic acid selected from the group consisting of hyaluronic acid and salts thereof to transport the drug percutaneously to the site of the pathology or trauma of the disease or condition wherein the form of hyaluronic acid is between about 1% and about 3% by weight of the composition having a molecular weight less than 750,000 daltons and greater than 150.000 daltons, and wherein the drug is between about 1% and about 5% by weight of the composition. 2. The composition of claim 1 suitable for topical application further comprising methoxypolyethylene glycol (20% by weight), benzyl alcohol (1% by weight), and sterile water in a container. 3. The composition of claim 2 wherein the form of hyaluronic acid is sodium hyaluronate and the drug is diclofenac sodium. |